Merck & Co., Inc. (NYSE:MRK) Announces Earnings Results, Beats Expectations By $0.03 EPS

Merck & Co., Inc. (NYSE:MRK) released its quarterly earnings results on Tuesday. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.03, Briefing.com reports. Merck & Co., Inc. had a return on equity of 44.54% and a net margin of 29.63%.The company had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. During the same quarter in the prior year, the company posted $1.72 EPS. The firm’s revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. updated its FY 2026 guidance to 5.000-5.150 EPS.

Here are the key takeaways from Merck & Co., Inc.’s conference call:

• Merck says its transformed portfolio gives line of sight to over $70 billion of potential commercial opportunity by the mid‑2030s (up ~$20 billion year‑over‑year), with about 10 programs that could be substantially de‑risked in the next two years.
• For 2026 Merck guided revenue of $65.5–$67.0 billion (1%–3% growth) and non‑GAAP EPS of $5.00–$5.15, with assumptions including ~82% gross margin and approximately $3 billion of share repurchases.
• Management highlighted strong R&D and launch momentum — including positive phase 3 results for oral PCSK9 candidate Enlicitide, positive Islatravir two‑drug HIV data, expanded approvals and uptake for Winrevair, and ongoing Keytruda launch progress (including the QLEX subcutaneous format).
• Near‑term profitability will be hit by large one‑time items and headwinds — Merck expects an approximately $9 billion one‑time Sedera charge plus ~$3.65 per share upfront Seagen costs (and ongoing financing costs), and cited roughly $2.5 billion of 2026 headwinds from generic competition, IRA pricing and the restructured Koselugo agreement.

Merck & Co., Inc. Trading Up 2.2%

NYSE:MRK traded up $2.50 during midday trading on Tuesday, reaching $115.87. 21,792,866 shares of the stock traded hands, compared to its average volume of 13,190,925. The stock has a market capitalization of $287.58 billion, a P/E ratio of 15.31, a PEG ratio of 1.55 and a beta of 0.28. The company has a fifty day moving average of $105.46 and a 200 day moving average of $92.23. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.44 and a current ratio of 1.66. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $118.46.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be issued a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, March 16th. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 44.91%.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q4 results beat consensus — Merck reported stronger-than-expected Q4 revenue and EPS, driven in large part by continued demand for cancer immunotherapy Keytruda; the quarter and earnings transcript highlight solid near-term operating momentum. Merck Q4 2025 Earnings Call Transcript
• Positive Sentiment: Pipeline and strategic investments emphasized — Management reiterated investment in oncology and a broad pipeline, and said it will pursue acquisitions and R&D to offset upcoming product challenges, which supports longer-term growth hopes. Business Wire — Q4 Results & Pipeline
• Neutral Sentiment: 2026 guidance provided — Merck set FY‑2026 adjusted EPS of $5.00–$5.15 and revenue of $65.5B–$67.0B, giving investors concrete targets to model, even though those ranges were lighter than some street forecasts. MarketWatch — 2026 Outlook
• Neutral Sentiment: Index/fund positioning discussion — Commentary on Merck’s standing in S&P/sector funds may affect passive flows but is not an immediate earnings driver. Kalkine Media — S&P Fund Positioning
• Negative Sentiment: Guidance missed Wall Street’s expectations — The FY‑2026 revenue and EPS ranges were below analysts’ consensus, prompting concern about near-term growth and triggering an initial sell-off. Reuters — 2026 Sales Forecast Below Estimates
• Negative Sentiment: Patent cliffs and generic competition risk — Management warned that patent expirations (notably Januvia) and other losses of exclusivity will pressure 2026 sales more than some analysts expected, raising near-term downside risk to revenue and margins. WSJ — Patent Losses and Slower Earnings Growth

Hedge Funds Weigh In On Merck & Co., Inc.

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of Merck & Co., Inc. by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock worth $26,770,014,000 after purchasing an additional 2,185,853 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Merck & Co., Inc. by 9.4% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 53,865,466 shares of the company’s stock valued at $4,263,991,000 after acquiring an additional 4,636,183 shares during the last quarter. DLD Asset Management LP grew its holdings in shares of Merck & Co., Inc. by 30.1% in the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock valued at $3,986,675,000 after purchasing an additional 11,000,000 shares in the last quarter. Norges Bank purchased a new position in shares of Merck & Co., Inc. in the second quarter valued at $2,858,570,000. Finally, Franklin Resources Inc. increased its position in Merck & Co., Inc. by 23.5% in the second quarter. Franklin Resources Inc. now owns 27,032,601 shares of the company’s stock worth $2,139,901,000 after purchasing an additional 5,135,748 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on MRK. UBS Group increased their price target on Merck & Co., Inc. from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Scotiabank raised their price target on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “sector outperform” rating in a research note on Thursday, December 4th. TD Cowen upped their price objective on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a research report on Tuesday, January 20th. Zacks Research lowered shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research report on Friday, January 9th. Finally, Wall Street Zen upgraded shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a report on Saturday. Eight equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $114.53.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.